Rx Medicare

Medicare News

Flower

Data Suggest Sodium Oxybate Significantly Improves Pain And The Core Symptoms Of Fibromyalgia

Jazz Pharmaceuticals’ (Nasdaq: JAZZ) sodium oxybate (JZP-6) demonstrated statistically significant and clinically meaningful improvement in pain and the core symptoms associated with fibromyalgia, according to Phase III data presented last week at the 2009 Associated Professional Sleep Societies meeting in Seattle, WA. These data have not been evaluated by the FDA or other regulatory authorities for use of sodium oxybate in the treatment of fibromyalgia.

Read More…

  • Share/Bookmark

Related Posts

Tags: , , , , , , , , ,

Comments are closed.